Product Description: Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].
Applications: Cancer-programmed cell death
Formula: C18H24ClN7OS
References: [1]TNO155: SHP2 inhibitor/[2]Liu C, et al. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Clin Cancer Res. 2021 Jan 1;27(1):342-354./[3]Weiss A, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022 Jun 2;12(6):1500-1517.
CAS Number: 1801765-04-7
Molecular Weight: 421.95
Compound Purity: 99.41
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Phosphatase;SHP2
Deutsch
English
